|
|
Post by bradleysbest on Dec 2, 2015 13:43:10 GMT -5
Tweet Sam (Afrezzauser) I am sure he would gladly meet with you.... I quoted the wrong post...Sorry |
|
|
|
Post by cathode on Dec 2, 2015 13:47:01 GMT -5
Yes, higher dose is needed Sweedee and Sanofi knows this. 20U is recommended by my source. Training for doctors speaking start February 2016. I personaly think clamp studies were needed for EMA filing. At this point in time, the Technosphere platform would allow for up to 36U on a cartridge. At I believe 24U and above, there is some different technology although not sure exactly what it is. Sanofi Google partnership has one more component which is the Google Dexcom partnership. The newest Dexcom sensor, the G5 sends data directly from the sensor to a smartphone. dexcom.com/media/dexcom-g5-mobile-cgm-systemGoogle is playing around a bit with a contact lens that measures glucose levels but as you all know, what Google is most proficient at is data analysis. Dexcom and Google are working on another sensor that will have a much lower price point, be smaller in diameter than a quarter and distributed at retail pharmacies.
With news being reported that UHC will have Afrezza on formulary 1-1-16, maybe Sanofi works with UHC to put 1000 type 1s on Afrezza and the G5 sensor system for 9 months and tests A1c every 6 weeks to show a before & after. I know we need trials etc for label change, but something like this would not be all that expensive and increase the awareness of the Afrezza value proposition exponentially. I hadn't heard of this and I follow DXCM a bit. I know they have a partnership with Alphabet Life Sciences just like SNY and Novartis (contact lens), but I have not seen any solid info on what they are doing with DXCM. Do you have a source for this statement? |
|
|
|
Post by dreamboatcruise on Dec 2, 2015 14:38:11 GMT -5
If anyone has channel to some of these Afrezza users invited to SD, I'd be really curious whether SNY has previously asked them to log data about dosing, diet, etc. and if so for how long... and is it being provided to SNY on a regular basis.
|
|
|
|
Post by docfrezza on Dec 2, 2015 14:55:54 GMT -5
I have confirmed with my Afrezza rep that this meeting is occurring. This is an advisory board meeting, not a speaker meeting. Topics to be discussed are not known. Typical advisory board meetings are 12-15 practitioners and 4-8 members of the brand team. FYI.
|
|
|
|
Post by EveningOfTheDay on Dec 2, 2015 15:06:21 GMT -5
I have confirmed with my Afrezza rep that this meeting is occurring. This is an advisory board meeting, not a speaker meeting. Topics to be discussed are not known. Typical advisory board meetings are 12-15 practitioners and 4-8 members of the brand team. FYI. This one seems to include early adopters too. Is that typical also? |
|
|
|
Post by jeremg on Dec 2, 2015 15:10:42 GMT -5
I have confirmed with my Afrezza rep that this meeting is occurring. This is an advisory board meeting, not a speaker meeting. Topics to be discussed are not known. Typical advisory board meetings are 12-15 practitioners and 4-8 members of the brand team. FYI. Could you sure the difference between an "advisory board meeting" and a "speaker meeting" for us laypersons? And what could be the implications of this "advisory board meeting"? Who is advising and on what? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 2, 2015 15:25:15 GMT -5
At this point in time, the Technosphere platform would allow for up to 36U on a cartridge. At I believe 24U and above, there is some different technology although not sure exactly what it is. Sanofi Google partnership has one more component which is the Google Dexcom partnership. The newest Dexcom sensor, the G5 sends data directly from the sensor to a smartphone. dexcom.com/media/dexcom-g5-mobile-cgm-systemGoogle is playing around a bit with a contact lens that measures glucose levels but as you all know, what Google is most proficient at is data analysis. Dexcom and Google are working on another sensor that will have a much lower price point, be smaller in diameter than a quarter and distributed at retail pharmacies.
With news being reported that UHC will have Afrezza on formulary 1-1-16, maybe Sanofi works with UHC to put 1000 type 1s on Afrezza and the G5 sensor system for 9 months and tests A1c every 6 weeks to show a before & after. I know we need trials etc for label change, but something like this would not be all that expensive and increase the awareness of the Afrezza value proposition exponentially. I hadn't heard of this and I follow DXCM a bit. I know they have a partnership with Alphabet Life Sciences just like SNY and Novartis (contact lens), but I have not seen any solid info on what they are doing with DXCM. Do you have a source for this statement? Google wants one thing, to own the data. It's all about the 0s and 1s. The hardware is chump change and rev share does not kick in until nearly $1B. diatribe.org/google-and-dexcom-team-dramatically-improve-cgmIn time, more of the burden, clinical and economic will be on the patient. Less practitioners, less money more do it yourself or deciding how you want to allocate your $$. Only a matter of time until the diabetic will wear a sensor, data auto uploaded into Google cloud, read and patient gets notice that all is good or to take a dose of Afrezza. Patient will be rewarded or penalized based on behavior. Big brother will know what they eat, activity level and Rx compliance. You don't want to wear the sensor, no worries, coverage drops and premium goes up. mobihealthnews.com/48885/gsk-ventures-into-connected-inhaler-space-with-propeller-health-deal/mobihealthnews.com/48953/the-future-of-health-sensing-may-get-under-your-skin/ |
|
|
|
Post by cathode on Dec 2, 2015 15:46:42 GMT -5
I hadn't heard of this and I follow DXCM a bit. I know they have a partnership with Alphabet Life Sciences just like SNY and Novartis (contact lens), but I have not seen any solid info on what they are doing with DXCM. Do you have a source for this statement? Google wants one thing, to own the data. It's all about the 0s and 1s. The hardware is chump change and rev share does not kick in until nearly $1B. diatribe.org/google-and-dexcom-team-dramatically-improve-cgmIn time, more of the burden, clinical and economic will be on the patient. Less practitioners, less money more do it yourself or deciding how you want to allocate your $$. Only a matter of time until the diabetic will wear a sensor, data auto uploaded into Google cloud, read and patient gets notice that all is good or to take a dose of Afrezza. Patient will be rewarded or penalized based on behavior. Big brother will know what they eat, activity level and Rx compliance. You don't want to wear the sensor, no worries, coverage drops and premium goes up. mobihealthnews.com/48885/gsk-ventures-into-connected-inhaler-space-with-propeller-health-deal/mobihealthnews.com/48953/the-future-of-health-sensing-may-get-under-your-skin/Thanks for pointing me to this. I don't know how I missed the actual description of what the DXCM Google Life Science collaboration entailed. I guess I just saw the press that they partnered. |
|
|
|
Post by bloodrootfc on Dec 2, 2015 16:12:14 GMT -5
I have confirmed with my Afrezza rep that this meeting is occurring. This is an advisory board meeting, not a speaker meeting. Topics to be discussed are not known. Typical advisory board meetings are 12-15 practitioners and 4-8 members of the brand team. FYI. advisory board? as in FDA? |
|
|
|
Post by bloodrootfc on Dec 2, 2015 16:13:22 GMT -5
I have confirmed with my Afrezza rep that this meeting is occurring. This is an advisory board meeting, not a speaker meeting. Topics to be discussed are not known. Typical advisory board meetings are 12-15 practitioners and 4-8 members of the brand team. FYI. If I remember correctly, MGMT said they were going to have patient input at their next FDA meeting |
|
|
|
Post by docfrezza on Dec 2, 2015 16:20:49 GMT -5
As I have been told the meeting is a practitioner's advisory board. This will likely involve the input of a small group of practitioners to discuss whatever topics the company wishes to discuss. What is to be discussed is not known by me. A speaker's training meeting would involve a larger number of practitioners being trained to lead presentations either locally, regionally, or nationally regarding Afrezza. This meeting is not a speaker's training meeting. I have no more information or specifics than this.
|
|
|
|
Post by rrtzmd on Dec 2, 2015 16:33:46 GMT -5
Here is the original post from YMB: oxotnik1 • 11 hours ago Flag 49 users liked this posts users disliked this posts 2 Reply This Friday, Dec 4th, SNY flying initial adopters to San Diego's Del Mar Hilton . for weekend meetings with scientists from SNY and UCSD. Topics include dosing and who knows what else. This would not be happening if SNY planned to drop MNKD. I will get updates and let all know next week. Afrezza user posted this comment on Twitter this AM: Afrezzauser afrezzauser · 1h1 hour ago On way to San Diego till Dec 6th! If anyone would like to meet I will try to do it. Send private message. #afrezza Referring to the rumor, Mr. Finta later tweeted: "Not sure where this is coming from but I wont comment, confirm or deny.I can tell you that I will be enjoying some sun." Seriously? Is this some sort of silly game? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Dec 2, 2015 17:28:32 GMT -5
Here is the original post from YMB: oxotnik1 • 11 hours ago Flag 49 users liked this posts users disliked this posts 2 Reply This Friday, Dec 4th, SNY flying initial adopters to San Diego's Del Mar Hilton . for weekend meetings with scientists from SNY and UCSD. Topics include dosing and who knows what else. This would not be happening if SNY planned to drop MNKD. I will get updates and let all know next week. Afrezza user posted this comment on Twitter this AM: Afrezzauser afrezzauser · 1h1 hour ago On way to San Diego till Dec 6th! If anyone would like to meet I will try to do it. Send private message. #afrezza Referring to the rumor, Mr. Finta later tweeted: "Not sure where this is coming from but I wont comment, confirm or deny.I can tell you that I will be enjoying some sun." Seriously? Is this some sort of silly game? Let your plans be dark and impenetrable as night, and when you move, fall like a thunderbolt. ― Sun Tzu, The Art of War |
|
|
|
Post by rrtzmd on Dec 2, 2015 17:44:29 GMT -5
Referring to the rumor, Mr. Finta later tweeted: "Not sure where this is coming from but I wont comment, confirm or deny.I can tell you that I will be enjoying some sun." Seriously? Is this some sort of silly game? Let your plans be dark and impenetrable as night, and when you move, fall like a thunderbolt. ― Sun Tzu, The Art of War "Let your plans be dark and impenetrable as night, and when you move, fall like a thunderbolt." It sounds like Sun Tzu was referring to MNKD and its stock price. |
|
|
|
Post by joeypotsandpans on Dec 2, 2015 17:45:51 GMT -5
Referring to the rumor, Mr. Finta later tweeted: "Not sure where this is coming from but I wont comment, confirm or deny.I can tell you that I will be enjoying some sun." Seriously? Is this some sort of silly game? Let your plans be dark and impenetrable as night, and when you move, fall like a thunderbolt. ― Sun Tzu, The Art of War Or for those that question is this some sort of silly game and have fallen into the crowd's "appearing to not know what they're doing" and suggestions of entitlement to know their (SNY's) chess moves ahead of time, etc etc Cliché: Dumb as a fox, To be Explanation: 1. To be smart or cunning while appearing not to know what you are doing. Country: Origin: The fox is known for its cunning and crafty ways. |
|
